HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Rijk-Zwikker, G. L. Articles by Huysmans, H. A. Search for Related Content PubMed PubMed Citation Articles by van Rijk-Zwikker, G. L. Articles by Huysmans, H. A.

European Journal of Cardio-Thoracic Surgery, Vol 5, 406-409, Copyright © 1991 by European Association for Cardio-thoracic Surgery

ARTICLES

Pulmonary metastasectomy in patients with osteosarcoma

GL van Rijk-Zwikker, MA Nooy, A Taminiau, AP Kappetein and HA Huysmans
Department of Cardiothoracic Surgery, Academisch Ziekenhuis, Leiden, The Netherlands.

Between 1980 and 1990, 70 patients with high malignant osteosarcoma of the extremities were treated according to the European Osteosarcoma Intergroup trials. Of the 31 patients with metachronous metastases (group I), 17 underwent pulmonary metastasectomy. Six of the 17 survived 8 months to 4 years after metastasectomy without evidence of recurrent metastatic disease. The type of orthopedic surgical treatment had no influence on the disease free interval (DFI), nor on the overall survival. The DFI was significantly longer (P less than 0.003) in patients with resectable pulmonary metastases. Overall survival was not influenced by the length of the DFI. Six of 11 patients with synchronous metastases (group II) underwent pulmonary metastasectomy, 1 survived longer than 7 months. Nevertheless, overall survival is not significantly different between group I and group II (P = 0.2): 28 patients without pulmonary metastases (group III) had a 95% survival at 5 years. In patients with metachronous metastases, metastasectomy independently had a positive effect on survival (P less than 0.001), but did not cure the patients. Strict patient selection and additional therapy to prevent micrometastases is needed to improve survival.

This article has been cited by other articles:

				O. S. Bruland, H. Hoifodt, G. Saeter, S. Smeland, and O. Fodstad Hematogenous Micrometastases in Osteosarcoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4666 - 4673. [Abstract] [Full Text] [PDF]

				B. Kempf-Bielack, S. S. Bielack, H. Jurgens, D. Branscheid, W. E. Berdel, G. U. Exner, U. Gobel, K. Helmke, G. Jundt, H. Kabisch, et al. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS) J. Clin. Oncol., January 20, 2005; 23(3): 559 - 568. [Abstract] [Full Text] [PDF]